NEW YORK, July 18, 2019 /PRNewswire/ — Centinel Spine, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced that it received Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA) to initiate a two-level clinical trial with two different prodisc® C Anterior Cervical Total Disc devices – prodiscC Vivo and prodiscC SK. The …